Minerva Neurosciences, Inc (NERV) Given Average Rating of “Hold” by Brokerages

Shares of Minerva Neurosciences, Inc (NASDAQ:NERV) have been assigned a consensus rating of “Hold” from the six analysts that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $16.00.

A number of analysts recently issued reports on NERV shares. Zacks Investment Research upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a report on Wednesday, September 13th. ValuEngine lowered Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a report on Sunday.

Shares of Minerva Neurosciences (NERV) opened at $6.15 on Thursday. The stock has a market capitalization of $238.01, a P/E ratio of -5.54 and a beta of 1.53. Minerva Neurosciences has a twelve month low of $4.80 and a twelve month high of $12.60.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter. During the same quarter in the previous year, the firm posted ($0.24) earnings per share. analysts expect that Minerva Neurosciences will post -1.28 earnings per share for the current fiscal year.

In other Minerva Neurosciences news, CFO Geoff Race sold 5,829 shares of the company’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $5.79, for a total transaction of $33,749.91. Following the completion of the sale, the chief financial officer now owns 197,698 shares in the company, valued at $1,144,671.42. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 12,590 shares of company stock valued at $73,073. 21.60% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. ProShare Advisors LLC lifted its holdings in Minerva Neurosciences by 1.4% during the second quarter. ProShare Advisors LLC now owns 21,063 shares of the biopharmaceutical company’s stock worth $186,000 after buying an additional 297 shares during the period. Nationwide Fund Advisors increased its position in shares of Minerva Neurosciences by 14.2% during the second quarter. Nationwide Fund Advisors now owns 13,005 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 1,616 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Minerva Neurosciences by 7.5% during the second quarter. California State Teachers Retirement System now owns 44,537 shares of the biopharmaceutical company’s stock worth $394,000 after purchasing an additional 3,100 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Minerva Neurosciences by 54.6% during the second quarter. Russell Investments Group Ltd. now owns 15,794 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 5,579 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Minerva Neurosciences by 38.8% during the second quarter. The Manufacturers Life Insurance Company now owns 22,359 shares of the biopharmaceutical company’s stock worth $198,000 after purchasing an additional 6,251 shares in the last quarter. Institutional investors own 73.68% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/04/minerva-neurosciences-inc-nerv-given-average-rating-of-hold-by-brokerages.html.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply